New PET tracer aims to reveal hidden myeloma spots

NCT ID NCT07660939

Not yet recruiting Diagnosis Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new radioactive tracer for PET/CT scans that targets a protein called GPRC5D found on multiple myeloma cells. About 50 adults with plasma cell disorders, including multiple myeloma, will receive the tracer and then undergo imaging. The goal is to see if this method finds disease lesions better than current scans, and to check its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GPRC5D-targeted radiotracer for PET/CT imaging
What this could lead to: If successful, this imaging method could help doctors find multiple myeloma lesions more accurately, potentially guiding better treatment decisions.
What could go wrong: This is an early phase I study with a small number of participants, so the tracer may not prove safe or effective in larger groups. It is a diagnostic test, not a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA (MM) PLASMA CELL DISORDERS

Contacts and locations

Locations

Peking University First Hospital

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.